Apyx Medical (NASDAQ:APYX) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Apyx Medical (NASDAQ:APYX) announced its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01, FiscalAI reports. Apyx Medical had a negative return on equity of 76.18% and a negative net margin of 14.78%.The company had revenue of $13.88 million during the quarter, compared to analysts’ expectations of $13.18 million.

Here are the key takeaways from Apyx Medical’s conference call:

• Second-quarter revenue rose 22% to $13.9 million, led by a 28% increase in surgical aesthetics sales to $12.4 million. Management attributed the growth to AYON adoption, higher international generator sales, and increased domestic single-use handpiece volume.
• AYON received FDA clearance for power-assisted liposuction, with initial shipments beginning in June and a broader commercial launch planned for the third quarter. Management said early surgeon feedback was “exceptional” and expects more than 95% of new AYON customers to include the PowerLipo attachment.
• Management highlighted clinical studies supporting Renuvion’s role in body contouring, including higher patient satisfaction and fewer abdominoplasty or revision procedures when combined with liposuction, while maintaining comparable complication rates.
• Profitability improved, with gross margin rising to 63.9%, operating loss narrowing to $1.8 million, and adjusted EBITDA loss improving to $0.7 million. However, operating cash use increased to $3.5 million, and the company ended the quarter with $27.6 million in cash.
• The company reaffirmed 2026 revenue guidance of $59 million to $60 million and expects OEM revenue to decline to approximately $5 million from $7.5 million in 2025. Tariffs are also pressuring margins, although potential tariff refunds are not included in current guidance.

Apyx Medical Stock Down 2.6%

APYX opened at $4.05 on Friday. Apyx Medical has a twelve month low of $1.70 and a twelve month high of $5.08. The company has a quick ratio of 4.79, a current ratio of 5.80 and a debt-to-equity ratio of 2.68. The company has a 50-day moving average price of $4.24 and a 200 day moving average price of $3.94. The company has a market cap of $169.74 million, a PE ratio of -20.25 and a beta of 1.39.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Wall Street Zen cut shares of Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. HC Wainwright started coverage on shares of Apyx Medical in a research note on Monday, July 13th. They issued a “buy” rating and a $7.00 target price for the company. Zacks Research raised shares of Apyx Medical to a “hold” rating in a report on Tuesday, July 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.60.

Institutional Investors Weigh In On Apyx Medical

Several institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC acquired a new position in shares of Apyx Medical during the third quarter valued at approximately $28,000. Osaic Holdings Inc. purchased a new stake in shares of Apyx Medical during the second quarter worth approximately $50,000. Franklin Resources Inc. acquired a new position in Apyx Medical in the 3rd quarter valued at $59,000. Hudson Bay Capital Management LP acquired a new position in Apyx Medical in the 4th quarter valued at $73,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Apyx Medical in the 4th quarter valued at $111,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.